<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3319">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04261907</url>
  </required_header>
  <id_info>
    <org_study_id>ASC09F-CTP-ZY-01</org_study_id>
    <nct_id>NCT04261907</nct_id>
  </id_info>
  <brief_title>Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection</brief_title>
  <official_title>A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ascletis Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital of Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Base on Arbidol antiviral therapy,the investigators conduct a randomized, open-label trial to
      evaluate and compare the safety and efficacy of ASC09 /ritonavir and lopinavir/ritonavir in
      patients with 2019-nCoV pneumonia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 7, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of composite adverse outcome</measure>
    <time_frame>14 days</time_frame>
    <description>Defined as(one of them) SPO2≤ 93% without oxygen supplementation, PaO2/FiO2 ≤ 300mmHg or RR ≥ 30 breaths per.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recovery</measure>
    <time_frame>14 days</time_frame>
    <description>Clinical recovery was defined as( one of them): sustained (48 hours) alleviation of illness based on symptom scores (fever, cough,diarrhea, myalgia, dyspnea) all being absent and no evidence for progression (newly-presented dyspnea, SpO2 decline ≥3%, respiratory rate ≥ 24 breaths per min without supplemental oxygen). Or undectable viral RNA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of no fever</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of no cough</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of no dyspnea</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of no requring supplemental oxygen</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of undectable viral RNA</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of mechanical ventilation</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ICU admission</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time and rate of laboratory indicators related to disease improvement to return to normal</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>2019-nCoV</condition>
  <arm_group>
    <arm_group_label>ASC09/ritonavir group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASC09/ritonavir (300mg/100mg tablet)+conventional standardized treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lopinavir/ritonavir group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lopinavir/ritonavir tablet (200mg / 50mg tablet)+conventional standardized treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASC09/ritonavir group</intervention_name>
    <description>ASC09/ritonavir(300mg/100mg tablet), one tablet each time, twice daily, for 14 days, +conventional standardized treatment</description>
    <arm_group_label>ASC09/ritonavir group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lopinavir/ritonavir group</intervention_name>
    <description>Lopinavir/ritonavir tablets(200mg / 50mg tablet), two tablets each time, twice daily, for 14 days, +conventional standardized treatment</description>
    <arm_group_label>lopinavir/ritonavir group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Aged between 18 and 75 years, extremes included, male or female

          -  2. Laboratory (RT-PCR) and clinical symptoms confirmed case of 2019-nCoV pneumonia,
             according to the official guideline &quot;Pneumonia Diagnosis and Treatment Scheme for
             Novel Coronavirus Infection (Trial Version 5)&quot;

          -  3. Hospitalised with a new onset respiratory illness (≤7 days since illness onset)

          -  4. No family planning within six months, and agree to take effective contraceptive
             measures throughout the study and for at least 30 days after the final study drug dose

          -  5. Must agree not to enroll in another study of an investigational agent prior to
             completion of Day 30 of study

          -  6. Informed Consent Form (ICF) signed voluntarily

        Exclusion Criteria:

          -  1. Severe 2019-nCoV pneumonia met one of the following criteria: respiratory distress,
             RR ≥ 30 times / min, or SaO2 / SpO2 ≤ 93% in resting state, or arterial partial
             pressure of oxygen (PaO2) /concentration of oxygen (FiO2) ≤ 300mmHg (1mmHg = 0.133kpa)

          -  2. Critical severe 2019-nCoV pneumonia met one of the following criteria: respiratory
             failure and mechanical ventilation required, or shock, or combined with other organ
             failure required ICU monitoring treatment

          -  3. Severe liver disease (e.g. Child Pugh score ≥ C, AST &gt; 5 times upper limit)

          -  4. Known allergic reaction to any of components of ASC09 / ritonavir compound tablets

          -  5. Patients with definite contraindications in the label of ritonavir

          -  6. Positive serum pregnancy test result for women with childbearing potential at
             screening

          -  7. Using HIV protease inhibitor drugs

          -  8. Not suitable for the study, in the opinion of the Investigator (e.g. patient may be
             transferred to another hospital during the study period, patient with multiple basic
             diseases, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yunqing Qiu, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaowei Xu, Master</last_name>
    <phone>+86 13605708066</phone>
    <email>xxw69@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jian Liu, Master</last_name>
    <phone>+86 13958054006</phone>
    <email>lindaliu87@zju.edu.cn</email>
  </overall_contact_backup>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 6, 2020</study_first_submitted>
  <study_first_submitted_qc>February 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

